Concerns Over the Pace of Brinsupri's Launch Impact Insmed (INSM)
ClearBridge Investments' Q2 2026 commentary for its Small Cap Growth Strategy highlighted concerns over the slow launch pace of Insmed’s drug, Brinsupri. Despite a strong biotech sector and robust returns in AI-related stocks, Insmed underperformed due to these worries. The Russell 2000 Growth Index rose by 25.6% during the quarter, driven largely by enthusiasm for generational technologies like AI. On July 23, 2026, shares of Insmed (NASDAQ:INSM) closed at $107.41 with a market cap of $23.28 billion and had gained 2.5% over the past year. ClearBridge noted that while it remains confident in Brinsupri’s long-term sales potential, recent stock weakness has been excessive. Truist also recently cut its price target for Insmed due to competitive pressures.
Tickers: $INSM
Topics: ClearBridge Investments Insmed Q2 performance Small Cap Growth Strategy